What Embecta (EMBC) Investors Are Talking About Today

Embecta logged a -4.2% change during today's afternoon session, and is now trading at a price of $24.86 per share. The S&P 500 index moved -0.7%. EMBC's trading volume is 415,218 compared to the stock's average volume of 622,519.

Embecta trades -11.21% away from its average analyst target price of $28 per share. The 2 analysts following the stock have set target prices ranging from $25 to $31, and on average have given Embecta a rating of hold.

If you are considering an investment in EMBC, you'll want to know the following:

  • Embecta has moved -44.8% over the last year, and the S&P 500 logged a change of -19.2%

  • Based on its trailing earning per share of 3.89, Embecta has a trailing 12 month Price to Earnings (P/E) ratio of 6.4 while the S&P 500 average is 15.97

  • EMBC has a forward P/E ratio of 11.0 based on its forward 12 month price to earnings (Eps) of $2.26 per share

  • Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes.

  • Based in Parsippany, the company has 1,900 full time employees and a market cap of $1,418,862,208. Embecta currently returns an annual dividend yield of 0.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.